Immunotherapy trial offers hope for Tough-to-Treat bile duct cancers
NCT ID NCT02829918
Summary
This study tested whether the immunotherapy drug nivolumab could help patients with advanced bile duct cancer that had stopped responding to standard chemotherapy. The trial enrolled 54 adults whose cancer had progressed despite previous treatments. Researchers measured whether the drug could shrink tumors and extend survival in this difficult-to-treat cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Cancer Center
Duarte, California, 91010, United States
-
Emory University Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.